News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD) Monday said it expects revenue for the fiscal 2023 to be in the range of $435 million - $450 million, same as the previous outlook.
On average, 3 analysts polled by Thomson-Reuters expect the company to report revenue of $444.01 million for the year.
For the year 2024, the company sees revenue between $435 million and $455 million.
Ironwood expects adjusted earnings before interest, taxes, depreciation, and amortization or EBITDA for fiscal 2023 to be a loss of $900 million, while seeing a gain of $150 million for fiscal 2024.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
